Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Last updated: August 14, 2026
Sponsor: Deciphera Pharmaceuticals, LLC
Overall Status: Active - Recruiting

Phase

1

Condition

Prostate Cancer, Early, Recurrent

Prostate Cancer

Renal Cell Carcinoma

Treatment

DCC-2812

Clinical Study ID

NCT06966024
DCC-2812-01-001
  • Ages > 18
  • All Genders

Study Summary

This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  • Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, orCastration-Resistant Prostate Cancer

  • Able to take oral medication

  • If a female is of childbearing potential, must have a negative pregnancy test priorto enrollment and all participants agree to follow the contraception requirements

  • Adequate organ function and electrolytes

Exclusion

Key Exclusion Criteria:

  • Received any prior anticancer therapy or any investigational therapy within aspecified timeframe prior to first dose of DCC-2812

  • Impaired cardiac function

  • Major surgery within 28 days of the first dose of study drug

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: DCC-2812
Phase: 1
Study Start date:
August 27, 2025
Estimated Completion Date:
February 28, 2029

Connect with a study center

  • Dana-Farber Cancer Institute

    Boston, Massachusetts 02215
    United States

    Active - Recruiting

  • University of Michigan

    Ann Arbor, Michigan 48109
    United States

    Active - Recruiting

  • Washington University School of Medicine

    St Louis, Missouri 63110
    United States

    Active - Recruiting

  • Cleveland Clinic

    Cleveland, Ohio 44195
    United States

    Active - Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania 19111
    United States

    Active - Recruiting

  • Vanderbilt- Ingram Cancer Center

    Nashville, Tennessee 37232
    United States

    Active - Recruiting

  • NEXT Oncology, Austin

    Austin, Texas 78758
    United States

    Active - Recruiting

  • NEXT Oncology, San Antonio

    San Antonio, Texas 78229
    United States

    Active - Recruiting

  • NEXT Austin

    Austin 4671654, Texas 4736286 78758
    United States

    Active - Recruiting

  • NEXT Oncology

    San Antonio 4726206, Texas 4736286 78229
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.